Expanding the Scope of HER2-targeted Medicine Neratinib to Combat Triple- Negative Breast Cancer by Inhibiting the EGFR-ERK-STAT3 Signaling Axis

Breast cancer is not a single disease but a collection of different conditions, each driven by its own set of biological signals. Some types of breast cancer are fueled by hormones like estrogen, while others are driven by a specific protein called HER2. Doctors have developed powerful medicines to block these signals, turning once-deadly diagnoses into manageable conditions. However, there is a particularly aggressive form known as triple-negative breast cancer. As the name suggests, this type lacks the three receptors that most common treatments target: estrogen, progesterone, and HER2. Without these specific handles, doctors have fewer options, often relying on general chemotherapy that attacks all rapidly dividing cells. This leaves many patients with a difficult prognosis, as the cancer can spread quickly and return with a vengeance.

Within the body, cancer cells often rely on internal communication networks to grow and survive. One such network involves a protein called EGFR, which acts like a switch on the cell's surface, telling the cell to divide. When this switch is stuck in the "on" position, it can trigger a chain reaction inside the cell, activating a master regulator protein called STAT3. This regulator then travels to the cell's command center to turn on genes that help the tumor grow, spread to other organs, and build new blood vessels to feed itself. In triple-negative breast cancer, this specific pathway is often highly active, making it a promising target for new treatments. The challenge has been finding a way to shut it down without causing severe side effects, as directly blocking the master regulator has historically been too toxic for patients.

A team of researchers at the Advanced Centre for Treatment, Research and Education in Cancer in India has explored a new strategy to tackle this problem. They investigated whether an existing drug, originally designed for a different type of breast cancer, could be repurposed to shut down this dangerous signaling chain in triple-negative cases. The drug in question is neratinib, which is already approved to treat HER2-positive breast cancer by blocking the HER2 protein. The researchers hypothesized that neratinib might also be able to block the EGFR switch and, perhaps surprisingly, the STAT3 regulator itself, effectively cutting off the cancer's fuel supply at multiple points.

To test this idea, the team began by looking at the molecular structure of the drug and the proteins it might target. Using computer simulations, they modeled how neratinib fits into the shapes of both EGFR and STAT3. The results were striking. While the drug was known to bind tightly to EGFR, the simulations showed it fit even more snugly into a specific pocket on the STAT3 protein. This pocket is crucial because it is where STAT3 molecules grab onto each other to form pairs, a necessary step for them to become active and travel to the cell's nucleus. The computer models suggested that neratinib could physically prevent STAT3 from pairing up, effectively neutralizing it before it could cause harm.

The researchers then moved from the computer to the laboratory to see if these predictions held true in living cells. They worked with triple-negative breast cancer cells that were known to have high levels of EGFR and STAT3 activity. First, they confirmed that these cells relied heavily on the STAT3 protein to grow and divide. When they blocked the STAT3 protein directly, the cells stopped multiplying, proving that this pathway was essential for their survival. Next, they treated the cells with neratinib. The drug worked exactly as the simulations predicted. It successfully stopped the EGFR switch from turning on, which in turn prevented the downstream activation of STAT3. More importantly, the drug also stopped STAT3 molecules from pairing up, even when the cells were stimulated to grow. This dual action meant that the cancer cells were being hit from two directions at once.

The effects of this double blockade were profound. In the lab dishes, the treated cells stopped growing, lost their ability to form new colonies, and began to die off. The drug also stopped the cells from moving and invading surrounding tissues, which are the first steps in cancer spreading to other parts of the body. The researchers observed that the treated cells showed signs of programmed cell death, a natural process where damaged cells are eliminated. Furthermore, the drug reduced the production of a protein called VEGF, which tumors use to build new blood vessels. By cutting off this supply line, the drug effectively starved the tumor of the resources it needed to expand.

To see if these results would translate to a living organism, the researchers tested the drug in mice with human triple-negative breast tumors implanted in their mammary tissue. This setup mimics how the cancer grows and spreads in a human body. The mice were given neratinib daily for over a month. The results were clear: the tumors in the treated mice grew much slower than those in the untreated group. When the researchers examined the mice at the end of the study, they found that the treated animals had significantly fewer cancer cells in their lungs, liver, and other organs. The drug also reduced the number of blood vessels growing into the tumors, confirming that it was disrupting the tumor's ability to feed itself. Throughout the treatment, the mice maintained their normal weight, suggesting the drug was effective without causing the severe toxicity that often limits cancer treatments.

The study also looked at the broader picture by analyzing data from thousands of breast cancer patients stored in public medical databases. They found that patients with triple-negative breast cancer who had high levels of EGFR expression tended to have poorer survival rates compared to those with lower levels. This confirmed that the specific group of patients the researchers were targeting—those with high EGFR and active STAT3 pathways—were indeed the ones most likely to suffer from aggressive disease. The analysis showed that the EGFR and STAT3 pathways were frequently turned on together in these patients, reinforcing the idea that a drug capable of blocking both would be highly beneficial for this specific subgroup.

This research suggests that neratinib, a drug already on the market, could be a powerful new tool for a specific group of triple-negative breast cancer patients. By blocking both the EGFR switch and the STAT3 regulator, the drug appears to disrupt the cancer's ability to grow, spread, and build its own blood supply. The findings are particularly encouraging because they offer a potential solution for a type of cancer that currently has very few targeted treatment options. While the study was conducted in cells and mice, the results provide a strong foundation for further testing. If future clinical trials confirm these findings, doctors may soon have a new way to treat the most aggressive forms of breast cancer by simply repurposing a medicine they already know how to use.